查找临床试验
已按「荨麻疹」检索，对应国际通用词 chronic urticaria
共找到 9 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步正在招募III 期中国有中心NCT07402213
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
China
年龄 18 Years – 不限
Jemincare
正在招募I 期 / II 期中国有中心NCT07717905
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
China
年龄 18 Years – 75 Years
Bambusa Therapeutics
正在招募II 期中国有中心NCT07415551
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Bulgaria、China、Poland、South Korea
年龄 18 Years – 75 Years
Yuhan Corporation
正在招募II 期中国有中心NCT06509334
Trial of JYB1904 in Chronic Spontaneous Urticaria.
China
年龄 18 Years – 不限
Jemincare
正在招募II 期中国有中心NCT07166211
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
China
年龄 18 Years – 75 Years
Keymed Biosciences Co.Ltd
正在招募II 期 / III 期中国有中心NCT06924762
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
China
年龄 18 Years – 74 Years
Second Xiangya Hospital of Central South University
正在招募II 期 / III 期中国有中心NCT07378527
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
China
年龄 18 Years – 75 Years
Beijing InnoCare Pharma Tech Co., Ltd.
正在招募I 期中国有中心NCT07005713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
China
年龄 18 Years – 70 Years
BeOne Medicines
正在招募II 期中国有中心NCT07219615
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
United States、Bulgaria、Canada、China、Germany 等 10 国
年龄 18 Years – 不限
Pfizer